Equities Analysts Offer Predictions for AWH FY2024 Earnings

Aspira Women’s Health Inc. (NASDAQ:AWH) – Investment analysts at William Blair upped their FY2024 EPS estimates for Aspira Women’s Health in a note issued to investors on Tuesday, November 26th. William Blair analyst A. Brackmann now expects that the company will earn ($1.07) per share for the year, up from their prior forecast of ($1.19). The consensus estimate for Aspira Women’s Health’s current full-year earnings is ($1.26) per share. William Blair also issued estimates for Aspira Women’s Health’s Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.57) EPS.

Several other research firms have also recently commented on AWH. StockNews.com began coverage on Aspira Women’s Health in a report on Monday. They issued a “hold” rating for the company. Alliance Global Partners cut their price objective on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research report on Wednesday, August 14th.

Aspira Women’s Health Trading Up 6.6 %

AWH stock opened at $0.81 on Thursday. The company has a market cap of $13.50 million, a price-to-earnings ratio of -0.68 and a beta of 1.44. The firm has a 50-day moving average of $0.83 and a two-hundred day moving average of $1.27. Aspira Women’s Health has a 12 month low of $0.67 and a 12 month high of $5.65.

Hedge Funds Weigh In On Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. increased its stake in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 236,396 shares of the company’s stock after purchasing an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned approximately 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent reporting period. 12.19% of the stock is currently owned by institutional investors and hedge funds.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.